Study concept and design: Al-Khatib, Fonarow, S. Hammill.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Al-Khatib, Hellkamp, S. Hammill.
Critical revision of the manuscript for important intellectual content: Fonarow, Mark, Curtis, Hernandez, Anstrom, Peterson, Sanders, Al-Khalidi, B. Hammill, Heidenreich, S. Hammill.
Statistical analysis: Hellkamp, Anstrom, Peterson, Al-Khalidi.
Obtained funding: Al-Khatib, Mark.
Administrative, technical, or material support: Peterson, B. Hammill, S. Hammill.
Study supervision: Peterson, S. Hammill.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Fonarow reported serving as a consultant for Novartis, Medtronic, Gambro, Bayer, Johnson & Johnson, Takeda, and The Medicines Company; receiving grants or grants pending from the National Institutes of Health; being employed by the Ahmanson Foundation ; and serving as the Eliot Corday chair of Cardiovascular Medicine and Science, UCLA. Dr Mark reported receiving grants from Medtronic, Eli Lilly, Gilead, and AstraZeneca and receiving personal fees from Janssen Pharmaceuticals. Dr Curtis reported receiving grants from Medtronic and Boston Scientific; receiving research and salary support from Johnson & Johnson, GlaxoSmithKline, the Agency for Healthcare Research and Quality, and the National Heart, Lung, and Blood Institute; Dr Curtis also has made a detailed listing of financial disclosures available at (http://www.dcri.org/research/coi.jsp). Dr Hernandez reported receiving consulting fees from Boston Scientific and a grant from Medtronic. Dr Anstrom reported receiving consulting fees from Abbott Vascular, AstraZeneca, Bristol-Meyers Squibb, Pfizer, GlaxoSmithKline, and Ikaria; receiving research support from AstraZeneca; and serving on data monitoring committees for Pfizer and Vertex, Dr Peterson reported receiving grants from Eli LIlly and Janssen Pharmaceuticals and receiving personal fees from Janssen Pharmaceuticals and Boehringer Ingelheim. No other authors reported disclosures.
Funding/Support: This analysis was funded by grant 1R01-HL093071-01A1 from the National Heart, Lung, and Blood Institute.
Role of the Sponsors: The National Heart, Lung, and Blood Institute had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Disclaimer: Dr Peterson, associate editor for JAMA, was not involved in the editorial review of or the decision to publish this article. Views expressed in this article are those of the authors and do not necessarily represent the official views of the National Heart, Lung, and Blood Institute. The manuscript was reviewed by the American College of Cardiology-NCDR ICD registry Research and Publications Committee and by the American Heart Association-Get With The Guidelines Publications Committee. The views expressed in this manuscript represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies identified at http://www.ncdr.com/webncdr/.The ICD registry is an initiative of the American College of Cardiology Foundation and the Heart Rhythm Society.